Biotech Values

[mcbio]

I am uncomfortable with RIGL's drug safety profile, especially for RA long term use. The market doubts whether it can clear regulatory hurdle easily even if it maintains phase II efficacy.

I want to revisit these prior comments from you in light of what RIGL disclosed during its recent Piper presentation (#msg-58251171). I assume your safety profile concerns center around the slight blood pressure increase that occurs in some patients. Given that RIGL is clearly tracking cardiovascular events in FosD patients and has seen no trend at all to date in FosD arms, what specific concerns do you have? This doesn't guarantee of course that the trend won't diverge in the future but, to date, the slight blood pressure increase (and temporary if antihypertensive medication is adjusted) has not led to any difference in cardiovascular outcomes.